S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma
| Autor: | Hisahiro Matsubara, Isamu Hoshino, Masaya Uesato, Yasunori Akutsu, Tsuguaki Kono, Wei Qin, Yoshihide Semba, Kazuo Narushima, Toru Tochigi, Toshiharu Hanaoka |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Time Factors Esophageal Neoplasms Anemia medicine.medical_treatment Antineoplastic Agents Gastroenterology Disease-Free Survival Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Aged Tegafur Aged 80 and over Chemotherapy Leukopenia Models Statistical business.industry Recurrent Esophageal Squamous Cell Carcinoma General Medicine Esophageal cancer Middle Aged medicine.disease Drug Combinations Oxonic Acid Treatment Outcome Toxicity Carcinoma Squamous Cell Disease Progression Female Esophageal Squamous Cell Carcinoma medicine.symptom Neoplasm Recurrence Local business Progressive disease |
| Zdroj: | Oncology. 84(5) |
| ISSN: | 1423-0232 |
| Popis: | Purpose: S-1 is widely used for various cancers. It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data. The purpose is to provide results of an analysis of S-1 monotherapy for unresectable and recurrent ESCC. Patients and Methods: Twenty patients with histologically proven ESCC who were previously treated with other chemo(radio)therapies were treated with S-1 alone as second- or third-line chemotherapy. Results: A complete response (CR) was observed in 1 case (5%). A partial response (PR), stable disease (SD), and progressive disease (PD) were seen in 4 (20.0%), 7 (35.0%), and 8 (40.0%) cases, respectively. Two cases (10%) of anemia, 1 case (5%) of leukopenia, 3 cases (15%) of fatigue, and 3 cases (15%) of diarrhea were observed as grade 3 toxicity; however, there were no cases of grade 4 toxicity. The 1-year progression-free survival (PFS) rate was 10.0%, and the median PFS was 100 days. The 1-year overall survival (OS) was 30.5%, and the median OS was 330 days. The 1-year PFS rate in CR/PR/SD and PD was 16.7 and 0%, and the median survival time was 120 and 40 days. Conclusion: S-1 is a promising new drug which can be used as a second- or third-line chemotherapy for ESCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|